Vnitr Lek 2024, 70(3):198-206 | DOI: 10.36290/vnl.2024.039

News in cardiology 2023

Veronika Puchnerová, Michael Jenąovský, Petr Oą»ádal, Jiří Bonaventura
Kardiologická klinika 2. LF UK a FN Motol
2. lékařská fakulta Univerzity Karlovy v Praze

This review summarizes the latest advances in cardiology published in 2023, which affect clinical practice. First, we discuss the European Society of Cardiology guidelines and clinical updates. Then, we present an overview of the most important clinical trials published within the last year.

Keywords: cardiology, guidelines, update, cardiomyopathy, heart failure, coronary syndromes, diabetes mellitus, infective endocarditis, clinical trials.

Accepted: April 26, 2024; Published: May 6, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Puchnerová V, Jenąovský M, Oą»ádal P, Bonaventura J. News in cardiology 2023. Vnitr Lek. 2024;70(3):198-206. doi: 10.36290/vnl.2024.039.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC). European heart journal. 2023 Oct 1;44(37):3503-626. Go to original source... Go to PubMed...
    2. Marx N, Federici M, Schütt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). European heart journal. 2023 Oct 14;44(39):4043-140. Go to original source... Go to PubMed...
    3. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). European Heart Journal: Acute Cardiovascular Care. 2024 Jan;13(1):55-161. Go to original source... Go to PubMed...
    4. Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC Guidelines for the management of endocarditis: Developed by the task force on the management of endocarditis of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Nuclear Medicine (EANM). European heart journal. 2023 Oct 14;44(39):3948-4042. Go to original source... Go to PubMed...
    5. McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2023 Oct 1;44(37):3627-39.
    6. Joosten LP, van Doorn S, van de Ven PM, et al. Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial. Circulation. 2024 Jan 23;149(4):279-89. Go to original source... Go to PubMed...
    7. Kirchhof P, Toennis T, Goette A, et al. Anticoagulation with edoxaban in patients with atrial high-rate episodes. New England Journal of Medicine. 2023 Sep 28;389(13):1167-79. Go to original source... Go to PubMed...
    8. Healey JS, Lopes RD, Granger CB, et al. Apixaban for stroke prevention in subclinical atrial fibrillation. New England Journal of Medicine. 2024 Jan 11;390(2):107-17. Go to original source... Go to PubMed...
    9. https://www.bayer.com/media/en-us/oceanic-af-study-stopped-early-due-to-lack-of-efficac
    10. Piccini JP, Caso V, Connolly SJ, et al. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. The lancet. 2022 Apr 9;399(10333):1383-90. Go to original source... Go to PubMed...
    11. Rajkumar CA, Foley MJ, Ahmed-Jushuf F, et al. A placebo-controlled trial of percutaneous coronary intervention for stable angina. New England Journal of Medicine. 2023 Dec 21;389(25):2319-30. Go to original source... Go to PubMed...
    12. Lee JM, Choi KH, Song YB, et al. Intravascular imaging-guided or angiography-guided complex PCI. New England Journal of Medicine. 2023 May 4;388(18):1668-79. Go to original source... Go to PubMed...
    13. Sorajja P, Whisenant B, Hamid N, et al. Transcatheter repair for patients with tricuspid regurgitation. New England Journal of Medicine. 2023 May 18;388(20):1833-42. Go to original source... Go to PubMed...
    14. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement in low-risk patients at five years. New England Journal of Medicine. 2023 Nov 23;389(21):1949-60. Go to original source... Go to PubMed...
    15. Maron DJ, Hochman JS, Reynolds HR, et al. Initial invasive or conservative strategy for stable coronary disease. New England Journal of Medicine. 2020 Apr 9;382(15):1395-407. Go to original source... Go to PubMed...
    16. Al-Lamee R, Thompson D, Dehbi HM, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. The Lancet. 2018 Jan 6;391(10115):31-40. Go to original source... Go to PubMed...
    17. Ajufo E, Nayak A, Mehra MR. Fallacies of Using the Win Ratio in Cardiovascular Trials: Challenges and Solutions. Basic to Translational Science. 2023 Jun 1;8(6):720-7. Go to original source... Go to PubMed...
    18. Leon MB, Mack MJ, Hahn RT, et al. Outcomes 2 years after transcatheter aortic valve replacement in patients at low surgical risk. Journal of the American College of Cardiology. 2021 Mar 9;77(9):1149-61. Go to original source... Go to PubMed...
    19. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature medicine. 2022 Oct;28(10):2083-91. Go to original source... Go to PubMed...
    20. Sattar N, Lee MM, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. The lancet Diabetes & endocrinology. 2021 Oct 1;9(10):653-62. Go to original source... Go to PubMed...
    21. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023 Dec 14;389(24):2221-32. Go to original source... Go to PubMed...
    22. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022 Jul 21;387(3):205-16. Go to original source... Go to PubMed...
    23. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet. 2023 Jun 26. Go to original source... Go to PubMed...
    24. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024 Jan 2;331(1):38-48. Go to original source... Go to PubMed...
    25. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. New England Journal of Medicine. 2023 Apr 13;388(15):1353-64. Go to original source... Go to PubMed...
    26. Bonaca MP, Hamburg NM, Creager MA. Contemporary medical management of peripheral artery disease. Circulation research. 2021 Jun 11;128(12):1868-84. Go to original source... Go to PubMed...
    27. Farber A, Menard MT, Conte MS, et al. Surgery or endovascular therapy for chronic limb-threatening ischemia. New England Journal of Medicine. 2022 Dec 22;387(25):2305-16. Go to original source... Go to PubMed...
    28. Cox Z, et al. DICTATE-AHF: Early Dapagliflozin Initiation in Acute Heart Failure. ESC Congress 2023, Amsterdam, European Society of Cardiology. https://www.escardio.org/The-ESC/Press-Office/Press-releases/DICTATE-AHF-trial-fails-to-meet-primary-endpoint-with-dapagliflozin-in-acute-heart-failure
    29. Borlaug BA, Jensen MD, Kitzman DW, et al. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovascular Research. 2022 Dec;118(18): 3434-3450. Go to original source... Go to PubMed...
    30. Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. New England Journal of Medicine. 2023 Sep 21;389(12):1069-84. Go to original source... Go to PubMed...
    31. Sohns C, Fox H, Marrouche NF, et al. Catheter ablation in end-stage heart failure with atrial fibrillation. New England Journal of Medicine. 2023 Oct 12;389(15):1380-9. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.